Welcome to our dedicated page for DNOW news (Ticker: $DNOW), a resource for investors and traders seeking the latest updates and insights on DNOW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DNOW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DNOW's position in the market.
DNOW Inc. (NYSE: DNOW) reported their first quarter 2024 results, showcasing impressive financial performance. The company generated $81 million in cash from operating activities and $563 million in revenue. Net income attributable to DNOW Inc. was $21 million, or $0.19 per diluted share. EBITDA reached $39 million, and the company completed the acquisition of Whitco Supply for $185 million in cash, bolstering their capabilities in the U.S. midstream market. With a debt-free balance sheet, $188 million in cash, and total liquidity of approximately $564 million, DNOW's CEO is optimistic about the company's future growth prospects, upgrading their 2024 full-year revenue outlook to a mid-to-high single-digit percentage range.